Celcuity shares are trading higher as the market continues to re-rate the stock around its next major catalyst: a U.S. FDA decision on gedatolisib. Celcuity disclosed that the FDA accepted its New Drug Application (NDA), granted Priority Review, and assigned a PDUFA goal date of July 17, 2026 for gedatolisib in HR+/HER2- PIK3CA wild-type advanced breast cancer—bringing a definitive regulatory timeline into view. (stocktitan.net)

Priority Review shortens the FDA review clock versus a standard review, which can pull forward the potential commercialization timeline and raise the probability-weighted value of the program. With a formal decision date now on the calendar, trading often becomes more catalyst-driven, with incremental buying on dips and sensitivity to any additional clinical, manufacturing, or labeling signals that might emerge ahead of July 17, 2026. (stocktitan.net)

In addition to the Priority Review milestone, Celcuity highlighted that results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 study were published in the Journal of Clinical Oncology, keeping attention on the dataset that underpins the NDA. Separately, Wall Street has responded to the priority-review setup with target increases (for example, Needham raised its price target to $122 from $95 while reiterating a Buy rating), adding fuel to the bullish positioning into mid-2026. (stocktitan.net)

The next meaningful checkpoints are (1) any FDA communications as the review progresses toward the July 17, 2026 goal date and (2) Celcuity’s expected topline results from the PIK3CA mutant cohort of VIKTORIA-1 in the second quarter of 2026, which could influence investor expectations about label expansion and long-term commercial potential. If broader market risk-off pressure returns, CELC’s near-term tape may still be dominated by catalyst timing, options activity, and biotech sentiment rather than fundamentals. (stocktitan.net)